| Literature DB >> 24194954 |
Qiuqin Tang1, Jing Li, Simin Zhang, Beilei Yuan, Hong Sun, Di Wu, Chuncheng Lu, Wei Wu, Yankai Xia, Hongjuan Ding, Lingqing Hu, Daozhen Chen, Jiahao Sha, Xinru Wang.
Abstract
Several molecular epidemiological studies have been conducted to examine the association between glutathione S-transferase mu-1 (GSTM1) and glutathione S-transferase theta-1 (GSTT1) null polymorphisms and childhood acute leukemia; however, the conclusions remain controversial. We performed an extensive meta-analysis on 26 published case-control studies with a total of 3252 cases and 5024 controls. Crude odds ratios (ORs) with 95% confidence interval were used to assess the strength of association between childhood acute leukemia risk and polymorphisms of GSTM1 and GSTT1. With respect to GSTM1 polymorphism, significantly increased risk of childhood acute leukemia was observed in the overall analysis (OR = 1.30; 95%CI, 1.11-1.51). Furthermore, a stratification analysis showed that the risk of GSTM1 polymorphism are associated with childhood acute leukemia in group of Asians (OR = 1.94; 95%CI, 1.53-2.46), Blacks (OR = 1.76; 95%CI, 1.07-2.91), ALL (OR = 1.33; 95%CI, 1.13-1.58), '< 100 cases and <100 controls' (OR = 1.79; 95%CI, 1.21-2.64), '≥ 100 cases and ≥ 100 controls' (OR = 1.25; 95%CI, 1.02-1.52), and population-based control source (OR = 1.40; 95%CI, 1.15-1.69). With respect to GSTT1 polymorphism, significant association with childhood acute leukemia risk was only found in subgroup of Asian. This meta-analysis supports that GSTM1 null polymorphism is capable of causing childhood acute leukemia susceptibility.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24194954 PMCID: PMC3806859 DOI: 10.1371/journal.pone.0078810
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Main characteristics of all studies of GSTM1 genotypes included in the meta-analysis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||||||||
| Chen CL | 1997 | USA | White | ALL | 163 | N/A | 85/78 | 213 | 18-60 | 111/102 | 73 (44.8) | 90 (55.2) | 99 (46.5) | 114 (53.5) | Population |
| Chen CL | 1997 | USA | Black | ALL | 34 | N/A | 22/12 | 203 | 18-60 | 103/100 | 20 (58.8) | 14 (41.2) | 147 (72.4) | 56 (27.6) | Population |
| Krajinovic M | 1999 | Canada | White | ALL | 174 | 1-21 | N/A | 304 | N/A | N/A | 61 (35.1) | 113 (64.9) | 148 (48.7) | 156 (51.3) | Population |
| Saadat I | 2000 | Iran | Asian | ALL | 38 | 3-13 | 26/12 | 75 | 3-13 | 48/27 | 17 (44.7) | 21 (55.3) | 51 (68.0) | 24 (32.0) | Population |
| Woo MH | 2000 | USA | White | AML | 40 | N/A | N/A | 160 | N/A | N/A | 25 (62.5) | 15 (37.5) | 69 (43.1) | 91 (56.9) | Hospital |
| Woo MH | 2000 | USA | Black | AML | 7 | N/A | N/A | 38 | N/A | N/A | 2 (28.6) | 5 (71.4) | 24 (63.2) | 14 (36.8) | Hospital |
| Woo MH | 2000 | USA | White | AML | 6 | N/A | N/A | 44 | N/A | N/A | 2 (33.3) | 4 (66.7) | 25 (56.8) | 19 (43.2) | Hospital |
| Davies SM | 2000 | USA | White | AML | 232 | N/A | N/A | 153 | N/A | N/A | 168 (72.4) | 64 (27.6) | 106 (69.3) | 47 (30.7) | Population |
| Davies SM | 2002 | USA | White | ALL | 616 | N/A | N/A | 532 | N/A | N/A | 285 (46.3) | 331 (53.7) | 246 (46.2) | 286 (53.8) | Hospital |
| Davies SM | 2002 | USA | Black | ALL | 35 | N/A | N/A | 201 | N/A | N/A | 21 (60.0) | 14 (40.0) | 137 (68.2) | 64 (31.8) | Hospital |
| Alves S | 2002 | Portugal | White | ALL | 47 | N/A | N/A | 102 | N/A | N/A | 15 (31.9) | 32 (68.1) | 52 (51.0) | 50 (49.0) | Population |
| Krajinovic M | 2002 | Canada | White | ALL | 269 | N/A | N/A | 301 | N/A | N/A | 118 (43.9) | 151 (56.1) | 160 (53.2) | 141 (46.8) | Hospital |
| Balta G | 2003 | Turkey | White | ALL | 139 | 0.58-17 | 96/48 | 185 | 0.58-17 | 120/65 | 62 (44.6) | 77 (55.4) | 84 (45.4) | 101 (54.6) | Population |
| Balta G | 2003 | Turkey | White | ANLL | 31 | 1-17 | 19/14 | 185 | 0.58-17 | 120/65 | 12 (38.7) | 19 (61.3) | 84 (45.4) | 101 (54.6) | Population |
| Barnettee P | 2004 | USA | White | ALL | 94 | N/A | N/A | 326 | N/A | N/A | 46 (48.9) | 48 (51.1) | 143 (43.9) | 183 (56.1) | Population |
| Canalle R | 2004 | Brazil | White | ALL | 113 | 0.22-18 | 73/40 | 221 | 18-58 | 159-62 | 65 (57.5) | 48 (42.5) | 120 (54.3) | 101 (45.7) | Population |
| Joseph T | 2004 | India | Asian | ALL | 118 | 0-14 | 77/41 | 118 | 0-14 | 77/41 | 70 (59.3) | 48 (40.7) | 89 (75.4) | 29 (24.6) | Hospital |
| Wang J | 2004 | China | Asian | ALL | 67 | N/A | N/A | 146 | N/A | N/A | 16 (23.9) | 51 (76.1) | 69 (47.3) | 77 (52.7) | Population |
| Wang J | 2004 | China | Asian | AML | 32 | N/A | N/A | 146 | N/A | N/A | 9 (28.1) | 23 (71.9) | 69 (47.3) | 77 (52.7) | Population |
| Clavel J | 2005 | France | White | ALL | 191 | < 15 | N/A | 105 | N/A | 57/48 | 97 (50.8) | 94 (49.2) | 55 (52.4) | 50 (47.6) | Hospital |
| Clavel J | 2005 | France | White | ANLL | 28 | < 15 | N/A | 105 | N/A | 57/48 | 14 (50.0) | 14 (50.0) | 55 (52.4) | 50 (47.6) | Hospital |
| Pakakasama S | 2005 | Thailand | Asian | ALL | 107 | 0.83-14.75 | 62/45 | 320 | N/A | 165/155 | 31 (29.0) | 76 (71.0) | 129 (40.3) | 191 (59.7) | Population |
| Aydin-Sayitoglu M | 2006 | Turkey | White | ALL | 119 | N/A | N/A | 140 | 16-59 | 73/67 | 41 (34.5) | 78 (65.5) | 63 (45.0) | 77 (55.0) | Population |
| Aydin-Sayitoglu M | 2006 | Turkey | White | AML | 44 | N/A | N/A | 140 | 16-59 | 73/67 | 16 (36.4) | 28 (63.6) | 63 (45.0) | 77 (55.0) | Population |
| Pigullo S | 2007 | Italy | White | ALL | 323 | < 18 | N/A | 384 | < 18 | N/A | 171 (52.9) | 152 (47.1) | 184 (47.9) | 200 (52.1) | Hospital |
| Chan JY | 2011 | Indonesia | Asian | ALL | 185 | 0.03-14 | 107/78 | 177 | N/A | 104/73 | 43 (23.2) | 142 (76.8) | 55 (31.1) | 122 (68.9) | Population |
a range of age (year); b male/female; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANLL, acute non-lymphoblastic leukemia; NA, not available.
Meta-analysis of case-control studies of GSTM1 and GSTT1 status and the risk of acute leukemia.
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
| 26 |
| < 0.001 | 55.5 | 24 | 1.02 (0.90-1.15) | 0.130 | 25.1% |
|
| ||||||||
|
| 6 |
| 0.577 | 0.0 | 5 |
| 0.962 | 0.0 |
|
| 3 |
| 0.523 | 0.0 | 3 | 1.24 (0.48-3.19) [ | 0.089 | 58.6 |
|
| 17 | 1.09 (0.93-1.28) [ | 0.018 | 47.7 | 16 | 1.02 (0.90-1.15) | 0.618 | 0.0 |
|
| ||||||||
|
| 20 |
| 0.001 | 59.0 | 16 | 1.02 (0.90-1.17) | 0.103 | 32.4 |
|
| 4 | 1.24 (0.70-2.19) [ | 0.018 | 63.2 | 6 | 1.14 (0.78-1.67) | 0.343 | 6.5 |
|
| 2 | 1.21 (0.69-2.14) | 0.757 | 0.0 | 2 | 0.53 (0.13-2.17) [ | 0.111 | 60.7 |
|
| ||||||||
|
| 3 |
| 0.882 | 0.0 | 2 | 2.61 (0.76-8.90) | 0.844 | 0.0 |
|
| 13 |
| 0.011 | 53.6 | 12 | 1.04 (0.90-1.20) | 0.537 | 0.0 |
|
| ||||||||
|
| 10 | 1.14 (0.88-1.47) [ | 0.009 | 58.9 | 9 | 0.94 (0.77-1.15) | 0.370 | 7.9 |
|
| 16 |
| 0.015 | 48.9 | 15 | 1.01 (0.90-1.14) | 0.106 | 32.8 |
a Random-effects model was used when the P-value for heterogeneity test was ≤ 0.1 or I 2 ≥ 50%, otherwise the fixed-effect model was used. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANLL, acute non-lymphoblastic leukemia.
Figure 1Forest plot of the GSTM1 null polymorphism and childhood acute leukemia risk in overall analysis.
Studies are plotted according to the last name of the first author. Horizontal lines represent 95% CI. Each square represents the OR point estimate and its size is proportional to the weight of the study. The diamond (and broken line) represents the overall summary estimate, with confidence interval given by its width. The unbroken vertical line is at the null value (OR = 1.0). CI, confidence interval; OR, odds ratio.
Figure 2Forest plot of the GSTT1 null polymorphism and childhood acute leukemia risk in overall analysis.
Studies are plotted according to the last name of the first author. Horizontal lines represent 95% CI. Each square represents the OR point estimate and its size is proportional to the weight of the study. The diamond (and broken line) represents the overall summary estimate, with confidence interval given by its width. The unbroken vertical line is at the null value (OR = 1.0). CI, confidence interval; OR, odds ratio.
Main characteristics of all studies of GSTT1 genotypes included in the meta-analysis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||||||||
| Chen CL | 1997 | USA | White | ALL | 163 | N/A | 85/78 | 213 | 18-60 | 111/102 | 140 (85.9) | 23 (14.1) | 181 (85.0) | 32 (15.0) | Population |
| Chen CL | 1997 | USA | Black | ALL | 34 | N/A | 22/12 | 203 | 18-60 | 103/100 | 22 (64.7) | 12 (35.3) | 154 (75.9) | 49 (24.1) | Population |
| Krajinovic M | 1999 | Canada | White | ALL | 176 | 1-21 | N/A | 274 | N/A | N/A | 148 (84.1) | 28 (15.9) | 227 (82.8) | 47 (17.2) | Population |
| Woo MH | 2000 | USA | White | AML | 40 | N/A | N/A | 160 | N/A | N/A | 33 (82.5) | 7 (17.5) | 138 (86.3) | 22 (13.8) | Hospital |
| Woo MH | 2000 | USA | Black | AML | 7 | N/A | N/A | 38 | N/A | N/A | 3 (42.9) | 4 (57.1) | 26 (68.4) | 12 (31.6) | Hospital |
| Woo MH | 2000 | USA | Hispanic | AML | 6 | N/A | N/A | 44 | N/A | N/A | 4 (66.7) | 2 (33.3) | 36 (81.8) | 8 (18.2) | Hospital |
| Davies SM | 2000 | USA | White | AML | 232 | N/A | N/A | 153 | N/A | N/A | 210 (90.5) | 22 (9.5) | 138 (90.2) | 15 (9.8) | Population |
| Davies SM | 2002 | USA | White | ALL | 616 | N/A | N/A | 532 | N/A | N/A | 520 (84.4) | 96 (15.6) | 445 (83.6) | 87 (16.4) | Hospital |
| Davies SM | 2002 | USA | Black | ALL | 35 | N/A | N/A | 201 | N/A | N/A | 29 (82.9) | 6 (17.1) | 145 (72.1) | 56 (27.9) | Hospital |
| Alves S | 2002 | Portugal | White | ALL | 47 | N/A | N/A | 102 | N/A | N/A | 38 (80.9) | 9 (19.1) | 76 (74.5) | 26 (25.5) | Population |
| Balta G | 2003 | Turkey | White | ALL | 139 | 0.58-17 | 96/48 | 185 | 0.58-17 | 120/65 | 110 (79.1) | 29 (20.9) | 143 (77.3) | 42 (22.7) | Population |
| Balta G | 2003 | Turkey | White | ANLL | 31 | 1-17 | 19/14 | 185 | 0.58-17 | 120/65 | 29 (93.5) | 2 (6.5) | 143 (77.3) | 42 (22.7) | Population |
| Barnettee P | 2004 | USA | White | ALL | 81 | N/A | N/A | 300 | N/A | N/A | 72 (88.9) | 9 (11.1) | 234 (78.0) | 66 (22.0) | Population |
| Canalle R | 2004 | Brazil | White | ALL | 113 | 0.33-18 | 73/40 | 221 | 18-58 | 159/62 | 88 (77.9) | 25 (22.1) | 178 (80.5) | 43 (19.5) | Population |
| Joseph T | 2004 | India | Asian | ALL | 118 | 0-14 | 77/41 | 118 | 0-14 | 77/41 | 101 (85.6) | 17 (14.4) | 108 (91.5) | 10 (8.5) | Hospital |
| Wang J | 2004 | China | Asian | ALL | 67 | 0.83-18 | 44/23 | 146 | N/A | N/A | 25 (37.3) | 42 (62.7) | 74 (50.7) | 72 (49.3) | Population |
| Wang J | 2004 | China | Asian | AML | 32 | N/A | N/A | 146 | N/A | N/A | 13 (40.6) | 19 (59.4) | 74 (50.3) | 72 (49.3) | Population |
| Clavel J | 2005 | France | White | ALL | 191 | < 15 | N/A | 105 | N/A | 57/48 | 149 (78) | 42 (22.0) | 82 (78.1) | 23 (21.9) | Hospital |
| Clavel J | 2005 | France | White | ANLL | 28 | < 15 | N/A | 105 | N/A | 57/48 | 22 (78.6) | 6 (21.4) | 82 (78.1) | 23 (21.9) | Hospital |
| Pakakasama S | 2005 | Thailand | Asian | ALL | 107 | 0.83-14.75 | 62/45 | 320 | N/A | 165/155 | 57 (53.3) | 50 (46.7) | 198 (61.9) | 122 (38.1) | Population |
| Aydin-Sayitoglu M | 2006 | Turkey | White | ALL | 119 | N/A | N/A | 140 | 16-59 | 73/67 | 90 (75.6) | 29 (24.4) | 111 (79.3) | 29 (20.7) | Population |
| Aydin-Sayitoglu M | 2006 | Turkey | White | AML | 44 | N/A | N/A | 140 | 16-59 | 73/67 | 38 (86.4) | 6 (13.6) | 111 (79.3) | 29 (20.7) | Population |
| Pigullo S | 2007 | Italy | White | ALL | 323 | < 18 | N/A | 384 | < 18 | N/A | 279 (86.4) | 44 (13.6) | 315 (82.0) | 69 (18.0) | Hospital |
| Chan JY | 2011 | Indonesia | Asian | ALL | 185 | 0.03-14 | 107/78 | 177 | N/A | 104/73 | 121 (65.4) | 64 (34.6) | 128 (72.3) | 49 (27.7) | Population |
a range of age (year); b male/female; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANLL, acute non-lymphoblastic leukemia.